HLB Decides to Issue 57 Billion KRW Worth of BW for "FA Acquisition Payment"
[Asia Economy Reporter Ji Yeon-jin] HL Biopharma announced on the 21st that it has decided to issue convertible bonds with warrants worth 57 billion KRW.
The bond maturity date is October 20, 2026, and the conversion into new shares can be exercised from October 22 next year. The exercise price is 51,262 KRW per share.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Hyundai Mobis, Key Supplier for Hyundai’s Atlas, Target Price Raised [Click eStock]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company stated that the entire proceeds from the bond issuance will be used as the acquisition cost for the unlisted corporation FA.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
